Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSMay 2021: InBios International, Inc. announced that it had received Emergency Use Authorization for its SCoV-2 Ag Detect Rapid Test from the U.S. Food and Drug Administration (FDA).
April 2021: ThermoFisher Scientific announced that it would acquire PPD, Inc. This acquisition would further expand the service offerings of ThermoFisher Scientific to pharma and biotech customers.
March 2020: DiaSorin Group signed a licensing and technology transfer agreement with TTP plc. This allows DiaSorin Group to have access to Puckdx, a flexible & low-cost platform developed by TTP for the automation of sample-to-answer diagnostic assays.
The global dengue testing market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The growing incidences of dengue-related infections, along with the development of low-cost and reliable testing kits, are expected to fuel the progress of this market. Along with these, there has been substantial growth in the number of researches related to the development of low-cost and reliable testing methods for dengue, which in turn is anticipated to bring a surge in the demand for these tests in the upcoming years. The growth of the market can also be attributed to factors such as the growing deployment of awareness programs for controlling the spread of dengue and the increase in extreme weather events attributed to climate change. Moreover, the climate change phenomenon and associated abnormal weather events have exacerbated the spread of dengue on a global level, owing to which it has started affecting the developed regions as well. According to the data collected from the World Health Organization, the reported number of infections caused due to dengue increased from 505,430 in 2000 to more than 2.4 million in 2010 and 5.2 million in 2019. The high burden of the disease leads to the increased need for dengue diagnostic tests, which is projected to contribute to market growth in the near future.
Get more information on this report: Download Sample PDF
The market is segmented on the basis of test type into ELISA-based test, RT-PCR amplification assay, dengue IgG/IgM rapid test, and others, out of which the ELISA-based test segment is anticipated to grab the largest share by the end of 2030 on account of its increasing adoption by end-users for diagnosing dengue. In addition, ELISA-based tests are used for the qualitative detection of dengue virus IgM antibodies and are considered to possess greater sensitivity in detecting dengue, which is also projected to contribute to the growth of the segment during the forecast period. Furthermore, based on end-user, the diagnostic centers segment in the global dengue testing market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that most of the dengue treatments are home-based ascribing to the development of an only mild form of illness. Thus, individuals prefer diagnostic centers for dengue testing.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the global dengue testing market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific is predicted to grab the largest share over the forecast period owing to the high prevalence of dengue virus infections in several countries of the region such as Malaysia, Philippines and Vietnam, and the increase in government expenditure on improving healthcare infrastructure along with growing emphasis on carrying out dengue awareness campaigns in the region. Furthermore, the market in North America is evaluated to grow significantly during the forecast period, accounting to the presence of leading market players and well-developed healthcare infrastructure in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the market on account of growing healthcare advancements and the rising risk factors of dengue virus infections in future induced by climate change. As per the factsheet of the World Health Organization published in 2021, Europe is a potential region for the possible outbreak of dengue. A secondary dengue vector belonging to the Asian region with the name Aedes albopictus had spread to more than 25 countries in the European region as a result of international trade in used tires and other products, which are a breeding ground for the dengue mosquito.
Get more information on this report: Download Sample PDF
The global dengue testing market is further classified on the basis of region as follows:
Our in-depth analysis of the global dengue testing market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The growing incidences of dengue-related infections and the development of low-cost and reliable testing kits are the key factors driving market growth.
The growing incidences of dengue-related infections and the development of low-cost and reliable testing kits are the key factors driving market growth.
The limited availability of effective diagnostic tools in lower economic regions and the low per capita income of population in less-developed countries are estimated to hamper market growth.
The market in Asia Pacific will provide ample growth opportunities owing to the high prevalence of dengue virus infections in several countries of the region.
The major players dominating the dengue testing market are Abbott Laboratories, InBios International, Inc., EUROIMMUN AG, and CERTEST BIOTEC SL, among others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by test type, end-user, and by region.
With respect to end-user, the diagnostic centers segment is anticipated to hold the largest market share owing to the greater preference of diagnostic centers for dengue testing.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
